Marker Therapeutics is trading at $0.99, down 5.28%, with the decline appearing consistent with broader biotech weakness.
- No company-specific announcement surfaced on October 8; the latest company press release found was dated September 22.
- Coverage cited XBI down 1.87% during Thursday morning trading.
- Broader risk-off sentiment, elevated yields and market declines offer context, but no source directly attributes the stock’s move to a single catalyst.